Hims & Hers to offer at-home blood draws, lean into ‘peptide innovations' with new acquisitions
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
Hims & Hers Health (HIMS) Projected to Post Quarterly Earnings on Monday
Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
SchaeffersResearch.com14h
Hims and Hers Stock Drops Weight as Earnings Loom
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS), Evolent Health (EVH) and Bausch Health Companies (BHC)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research ...
Business Wire17h
Hims & Hers Acquires US-based Peptide Facility
Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s lon ...
Hosted on MSN3d
Hims & Hers Stock Jumps 156.9% in Three Months: What's Next?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...